We confirm that epilepsy is a pervasive symptom in SLC13A5 citrate transporter disorder (Thevenon et al., 2014; Hardies et al., 2015; Klotz et al., 2016; Schossig et al., 2017; Matricardi et al., 2020; Yang et al., 2020). Here, SLC13A5 is linked to epilepsy.